Ovarian Cancer

>

Latest News

Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months in patients with platinum-resistant ovarian cancer.
FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer

July 15th 2025

Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months, respectively, in patients with platinum-resistant ovarian cancer.

Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype
Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype

July 14th 2025

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.
PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer

June 4th 2025

Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.
Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer

June 2nd 2025

Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer
Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer

June 2nd 2025

Video Series
Video Interviews
Podcasts
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Latest CME Events & Activities

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

PER's Satellite Symposia at MHS

August 1-2, 2025

Register Now!

9th Annual School of Nursing Oncology™

August 9, 2025

Register Now!

Oncology Town Hall™ 2025 ESMO-GI Congress Highlights: The Latest Data on Immune-Based Strategies Across Hepatobiliary Cancers

View More

Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options

View More

8th Annual Live Medical Crossfire®: Hematologic Malignancies

View More

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and AD...

September 6, 2025

Register Now!

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View More

Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care

View More

Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma

View More

Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes

View More

Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches

View More

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

View More

Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Register Now!

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

View More

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

View More

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

View More

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

View More

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

View More

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

View More

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

View More

Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?

View More

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

View More

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

View More

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

View More

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

View More

More News